Clinical trial NCT06055764: Role of FDG PET/CT in Patients With Metastasis of Unknown Origin
Official title: Role of FDG PET/CT in Patients With Metastasis of Unknown Origin
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Metastasis
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-09-28
Enrollment: 73
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will recruit patients with suspected or proven MUO referred to the nuclear medicine unit to detect primary site.

Brief summary: Evaluatation of the role of F18FDG-PET/CT in patients with metastases of unknown origin.

Detailed description: Cancer of unknown primary origin (CUP) includes a cluster of heterogeneous tumors that have exceptional clinical features: it is defined as early apparent metastatic disease with no recognizable primary site at the time of presentation. The incidence of CUP ranges around 2% of all new cancer diagnoses.

The work up list of CUP include; a biopsy proven malignancy, a detailed physical examination, many laboratory, radiological and endoscopy. However, these investigations may be costly time-consuming and may eventually fail to detect the site of the primary malignant tumor in the majority of patients. In this context, positron-emission tomography (PET) combined with computed tomography (PET/CT), using the radiotracer 18F fluoro- 2-deoxyglucose (FDG) is an alternative, non-invasive imaging modality with accurate diagnostic performance. It considered good tool for diagnosis of patients with CUP . The basis for use of FDG as radiotracer for PET imaging in CUP depends on the fact that most of the malignant cancer phenotypes show an increased glucose metabolism rate.

Failure to identify the primary tumor hampers optimization of management planning, which in turn may adversely influence patient prognosis.

Eligibility criteria: Inclusion Criteria:

* Patients with age more than 18 years presented with either pathologically proved metastases of unknown primary or
* Patients with clinico-radiological suspicious of having metastases.

Exclusion Criteria:

* • Age below 18 years,

  * patients with pathologically proved primary tumor,
  * Patients suffering from advanced disease and in-cooperative patients.
  * Pregnant and lactating women.
  * Patients who had motion artifacts, or those who can't stay stable or calm during acquisition.

Primary outcomes:
measure: Role of FDG PET/CT in patients with metastasis of unknown origin. Role of FDG PET/CT in patients with metastasis of unknown origin.
timeFrame: through study completion an average 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Assiut University
name: Esraa Mamdouh
role: PRINCIPAL_INVESTIGATOR
References:
citation: Park JS, Yim JJ, Kang WJ, Chung JK, Yoo CG, Kim YW, Han SK, Shim YS, Lee SM. Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT. BMC Res Notes. 2011 Mar 9;4:56. doi: 10.1186/1756-0500-4-56.
citation: Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009 Mar;19(3):731-44. doi: 10.1007/s00330-008-1194-4. Epub 2008 Oct 17.